INFANTS via maternal immunisation *
ADULTS aged ≥60 years †
Recombinant respiratory syncytial virus pre-fusion F protein vaccine
2 INDICATIONS, 1 VACCINE 1, 2
INFANTS via maternal immunisation *
ADULTS aged ≥60 years †
Recombinant respiratory syncytial virus pre-fusion F protein vaccine
EVERY
BREATH
MATTERS.
ABRYSVO is recommended in the Australian Immunisation Handbook to help protect both infants,* via maternal immunisation, and adults aged ≥60 years † against respiratory syncytial virus( RSV). 2
* Active immunisation of pregnant women at 28 – 36 weeks gestation. 1, 2
†
Active immunisation of adults aged ≥75 years, Aboriginal and Torres Strait Islander adults aged ≥60 years, and adults aged ≥60 years with risk factors for severe RSV disease. 1, 2
2 Scan to view RSV
Now NIP-funded for pregnant n women recommendations
This vaccine is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www. tga. gov. au / reporting-problems.
PBS Information: ABRYSVO is listed on the NIP for pregnant women( 28 – 36 weeks gestation) only and is not listed on the PBS.
Before prescribing, please review the Approved Product Information by scanning the QR code.
ABRYSVO should be used in accordance with official recommendations. 1, 2
ABRYSVO ®( recombinant respiratory syncytial virus pre-fusion F protein) 120 micrograms / 0.5 mL bivalent vaccine powder for injection vial and diluent syringe
Indications: Active immunisation of pregnant women( 24-36 weeks gestation) for prevention of lower respiratory tract disease caused by RSV in infants( birth through 6 months); Active immunisation of individuals( 60 years and above) for prevention of lower respiratory tract disease caused by RSV. Use ABRYSVO in accordance with official recommendations. Contraindications: Hypersensitivity to the active ingredient or to any of the excipients. Precautions: Appropriate treatment and supervision must be readily available in case of a rare anaphylactic reaction. Consider the risks of intramuscular injection in thrombocytopenia or coagulation disorders. Postpone in acute febrile illness. Anxiety-related reactions including syncope can occur following / before any vaccination. Immunocompromised individuals, including individuals receiving immunosuppressant therapy, may have a diminished immune response. No studies in pregnant individuals < 24 weeks gestation. Protection may not be conferred in all individuals. Not for active immunisation in children. See PI for details. Interactions with other Medicines: Can be administered concomitantly, at different injection sites, with seasonal influenza vaccine and COVID-19 mRNA vaccines. Immunogenicity data indicated non-inferiority in immune response to RSV, diphtheria and tetanus components compared to ABRYSVO or dTpa administered alone. Immune response to the pertussis component of dTpa was lower in concomitant administration than dTpa administered alone. The clinical relevance of this is unknown. See PI for details. Adverse Effects: Headache, myalgia, vaccination site pain, vaccination site redness, vaccination site swelling, Guillain-Barré syndrome, hypersensitivity. See PI for details. Dosage and Administration: Single( 0.5 mL) dose. For intramuscular use only. See PI for details. V10324.